Programmed cell death‐L1 (PD‐L1) expression has been identified as one of the biomarkers used in response to ICIs. 6The percentage of PD‐L1 expression in the tumor tissue can be used as a predictor of the efficacy of pembrolizumab in non‐small cell lung cancer (NSCLC).7 The gene discussed is CD274; the disease is neoplasm.